Celltrion Healthcare’s Vegzelma (biosimilar, bevacizumab) Receives the Health Canada’s Approval for the Treatment of Cancer
Shots:
- Health Canada granted a NOC for Vegzelma, a biosimilar to Avastin for multiple forms of cancer i.e., mCRC, NSCLC, epithelial ovarian, FTC, PPC & glioblastoma
- Health Canada authorization was based on a comprehensive data package of analytical, preclinical & clinical studies which revealed that in terms of effectiveness, safety & PK, Vegzelma was highly similar to Avastin
- The company offers a patient support program i.e., CELLTRION CONNECT to provide access to patients & healthcare for Vegzelma treatment & also offers guidance with reimbursement navigation, financial assistance, inj. and nurse support services & pharmacy support services to eligible patients. Vegzelma was approved in the EU in Aug 2022 while UK & Japan in Sept 2022
Ref: Newswire | Image: Celltrion
Related News:- Celltrion’s Vegzelma (biosimilar, bevacizumab) Receives the US FDA’s Approval for the Treatment of Cancers
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
